Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced a publication in Nature led by researchers from Memorial Sloan Kettering Cancer Center (MSK) that could broaden the potential benefits for KRAS G12C inhibitors like sotorasib (brand name Lumakras) in patients with lung cancer and other solid tumors. Mission Bio’s Tapestri Platform empowered researchers to understand how resistance evolves against these lung cancer drugs by identifying secondary mutations within individual cancer cells that allowed them to bypass the therapeutic effect.
